<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Membranous nephropathy: Pathogenesis and etiology</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Membranous nephropathy: Pathogenesis and etiology</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Membranous nephropathy: Pathogenesis and etiology</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurence H Beck, Jr, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David J Salant, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 16, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in adults without diabetes, accounting for up to one-third of biopsy diagnoses in some regions. The term MN reflects a pattern of injury found by histopathologic examination of the kidney biopsy: glomerular basement membrane (GBM) thickening and subepithelial immunoglobulin-containing deposits with little or no cellular proliferation or infiltration.</p><p>MN in adults is most often "primary" (approximately 75 to 80 percent of cases) and caused by circulating autoantibodies against podocyte antigens. In approximately 20 to 25 percent of cases in adults, the MN lesion is associated with various disorders, including infections (such as hepatitis B and syphilis); autoimmune diseases; malignancies; allogeneic hematopoietic stem cell transplantation; and the use of certain drugs such as nonsteroidal antiinflammatory drugs (NSAIDs), alpha-lipoic acid, and certain traditional medicines.</p><p>The epidemiology, pathogenesis, and etiology of MN will be reviewed here. Other aspects of MN are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117886.html" rel="external">"Membranous nephropathy: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7341.html" rel="external">"Membranous nephropathy and kidney transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H2537529650"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>MN accounts for approximately 20 to 30 percent of cases of the nephrotic syndrome in White adults [<a href="#rid1">1,2</a>]. A rising incidence has been reported in China, perhaps related to environmental pollution [<a href="#rid3">3</a>]. (See <a class="local">'Environmental factors'</a> below.)</p><p>MN is seen in all ethnic and racial groups and in all sexes, but primary MN is more common in White males over the age of 40 years. MN in young females should raise the suspicion of systemic lupus erythematosus (SLE). MN is less commonly seen in children, in whom it is often associated with hepatitis B or, less commonly, autoimmune or thyroid disease [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H463479322"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>MN is an autoimmune disease that is characterized by thickening of the glomerular basement membrane (GBM) due to subepithelial immune complex deposition. In primary MN, circulating autoantibodies bind to endogenous antigens on the surface of glomerular podocytes, activating complement and inducing podocyte injury. In secondary MN, it is thought that circulating antigens (endogenous or exogenous), immune complexes, or even monoclonal immunoglobulins may become "planted" on the subepithelial side of the GBM and initiate immune complex formation.</p><p class="headingAnchor" id="H3566817899"><span class="h2">Target antigens and autoantibodies</span><span class="headingEndMark"> — </span>The development of autoantibodies directed against endogenous or exogenous target antigens is thought to be the initial step in the pathogenesis of MN. What exactly triggers loss of immune tolerance to these antigens and autoantibody production in MN is not known. A discussion of these target antigens is presented below.</p><p class="headingAnchor" id="H372203095"><span class="h3">Phospholipase A2 receptor</span><span class="headingEndMark"> — </span>The M-type phospholipase A2 receptor (PLA2R), a transmembrane receptor that is highly expressed in glomerular podocytes, is the major target antigen in human primary MN (up to 80 percent of cases) [<a href="#rid5">5</a>]. The specific role of PLA2R in the glomerulus is not known.</p><p>In the original description of PLA2R as a target antigen, circulating autoantibodies to PLA2R were identified in 26 of 37 (70 percent) patients with primary MN and could be associated with disease activity in patients for whom serial serum samples were available [<a href="#rid5">5</a>]. By contrast, there was no evidence of PLA2R antibodies in serum from eight patients with secondary MN due to systemic lupus erythematosus (SLE) or hepatitis B, from 15 patients with proteinuric conditions other than MN (such as diabetic kidney disease or focal segmental glomerulosclerosis), or from 30 healthy control individuals. The circulating anti-PLA2R antibodies were predominantly immunoglobulin (Ig) G4, the IgG subclass that is most abundant in the glomerular immune deposits in primary (but not secondary) MN. PLA2R colocalized with IgG4 in immune deposits of kidney tissue obtained by kidney biopsy from patients with MN, and anti-PLA2R antibodies could be eluted from this tissue. This was in contrast to the findings in secondary MN biopsies, in which there was no colocalization of IgG4 and PLA2R and from which no anti-PLA2R antibodies could be eluted.</p><p>Most if not all patients with PLA2R-associated MN have antibodies that target the N-terminal cysteine-rich region of the PLA2R protein [<a href="#rid6">6-8</a>]. The dominant epitope for anti-PLA2R has been shown to lie within the three most N-terminal domains [<a href="#rid6">6,7</a>]. As many as 80 percent of patients exhibit reactivity to epitopes within the first and seventh C-type lectin-like domains in addition to the N-terminal cysteine-rich domain (so-called epitope spreading) [<a href="#rid9">9</a>], while a smaller proportion of patients display reactivity to the eighth C-type lectin-like domain [<a href="#rid10">10</a>]. Epitope spreading may be associated with a lower spontaneous remission rate, a higher risk of chronic kidney disease, and a lower response rate to treatment with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid9">9,11</a>]. However, others have argued that it is the higher antibody titer associated with epitope spreading, rather than the spreading per se, that determines the outcome and response to treatment [<a href="#rid10">10</a>]. A study that finely mapped the key amino acids within the dominant epitope in the cysteine-rich domain has suggested that all the known B cell epitopes may lie on one side of the molecule, forming an immunogenic patch [<a href="#rid12">12</a>]. </p><p>Approximately 70 to 80 percent of patients with primary MN have circulating anti-PLA2R antibodies [<a href="#rid13">13-18</a>], and several studies have shown that anti-PLA2R seropositivity correlates with clinical disease activity. As examples, one study found that anti-PLA2R levels strongly correlated with clinical status [<a href="#rid15">15</a>]; another reported that lower anti-PLA2R titers were associated with a higher rate of spontaneous remission [<a href="#rid16">16</a>], and in two other studies, a decline in anti-PLA2R titers predicted the clinical response to immunosuppressive therapy [<a href="#rid18">18,19</a>]. One study identified autoantibodies in the banked serum of a substantial proportion of military recruits with PLA2R-associated MN weeks to months before the onset of clinical disease and in none of the banked samples of matched controls [<a href="#rid20">20</a>]. The sensitivity and specificity of anti-PLA2R autoantibodies in individuals with immunologically active primary MN have enabled the development of a serologic immunoassay for the noninvasive diagnosis of primary MN and monitoring of disease activity. (See  <a class="medical medical_review" href="/z/d/html/117886.html" rel="external">"Membranous nephropathy: Clinical manifestations and diagnosis", section on 'Anti-PLA2R antibody testing'</a>.)</p><p>Staining the kidney biopsy specimen for PLA2R, either by immunofluorescence or immunohistochemistry, provides another assay by which to identify PLA2R-associated primary MN [<a href="#rid13">13,21,22</a>]. In one study that reported a relatively low sensitivity of circulating anti-PLA2R (57 percent), an additional 24 percent of patients who did not have circulating antibodies had the PLA2R antigen detected within immune deposits by immunofluorescence of the biopsy specimen [<a href="#rid13">13</a>]. This may occur as patients enter serologic remission with still unresolved proteinuria and persistent immune deposits in glomeruli. Theoretically, it could also occur in the early stages of disease as anti-PLA2R antibodies are "soaked up" in the immune deposits and have not yet reached sufficiently high levels to be detected in the serum by existing immunoassays  (<a class="graphic graphic_figure graphicRef114639" href="/z/d/graphic/114639.html" rel="external">figure 1</a>) [<a href="#rid23">23-25</a>]. In general, tissue staining for PLA2R may be more sensitive (69 to 84 percent in various studies) than circulating anti-PLA2R in patients with primary MN [<a href="#rid13">13,21,22,26,27</a>]. Specificity is close to 100 percent; however, PLA2R has been detected in the immune deposits of some patients with secondary MN associated with hepatitis B virus (HBV) infection, neoplasms, nonsteroidal antiinflammatory drug (NSAID) use, or sarcoidosis but not lupus nephritis (LN) [<a href="#rid21">21,22,26,27</a>]. It is possible that this represents a coincidental association, and we regard such cases as having PLA2R-associated MN.</p><p>The association of anti-PLA2R autoantibodies with disease suggests a causal role, which has now been confirmed in passive and active immunization models in experimental animals as discussed below. (See <a class="local">'Mechanisms of podocyte injury'</a> below.)</p><p class="headingAnchor" id="H2963369939"><span class="h3">Other antigens</span><span class="headingEndMark"> — </span>Several other proteins have been identified in the glomerular immune deposits of patients with MN, several of which fulfill criteria as target antigens. Each antigen-associated MN discussed below has its own characteristic features, including patient characteristics, histopathologic characteristics, and disease associations. </p><p>Many of these novel antigens have been identified by means of laser microdissection of glomeruli followed by mass spectrometry, with the premise that the antigen has accumulated in glomerular immune deposits compared with other proteins and is unique to a subset of patients with MN. Confirmation of the antigen involves immunofluorescence/immunohistochemistry studies showing granular subepithelial staining of the antigen and colocalization of the antigen with IgG along the capillary walls, elution of antigen-specific IgG from frozen biopsy material, and demonstration of circulating antibodies to the antigen in the serum. Not all of these criteria have been met for some of the reported targeted antigens listed below. The role of these antigens in the pathogenesis of MN remains unclear for most antigens.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombospondin type-1 domain-containing 7A (THSD7A)</strong> – THSD7A is, like PLA2R, a transmembrane protein expressed on podocytes [<a href="#rid28">28,29</a>]. THSD7A may be the responsible antigen in approximately 3 percent of patients with primary MN [<a href="#rid30">30</a>]. The association of THSD7A with MN was examined in a study of 154 patients with anti-PLA2R-negative primary MN, 74 patients with anti-PLA2R-positive primary MN, 76 patients with other glomerular disease, and 44 healthy controls [<a href="#rid28">28</a>]. Autoantibodies specific for THSD7A were identified in sera from 15 of 154 patients with anti-PLA2R-negative primary MN but not in the sera from other individuals. In addition, the IgG that was eluted from the kidney biopsies of 1 of these 15 patients was specific for THSD7A, providing further support that THSD7A was the target antigen in these patients. THSD7A-associated MN has been found at a low frequency in American, European, and Chinese [<a href="#rid31">31,32</a>] cohorts, but it may be more prevalent in Japanese patients with primary MN [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1">THSD7A may also be involved in the pathogenesis of some cases of malignancy-associated MN [<a href="#rid34">34</a>]. As an example, in one case report of a patient with anti-PLA2R-negative MN and concomitantly diagnosed adenoneuroendocrine carcinoma of the gallbladder, the expression of THSD7A was detected by immunohistochemistry on tumor cells but not on normal gallbladder tissue [<a href="#rid34">34</a>]. The patient also had elevated plasma levels of anti-THSD7A antibodies, which the authors proposed were formed against abnormally expressed THSD7A by tumor cells. Treatment with chemotherapy led to the disappearance of THSD7A antibodies in the plasma within two weeks and a marked reduction in proteinuria. Other studies have found a higher rate of malignancy (ranging from 20 to 50 percent) among patients with THSD7A-associated MN [<a href="#rid35">35,36</a>]. However, in one study of 31 patients with THSD7A-associated MN, only two (6 percent) had a history of malignancy, and none were diagnosed with malignancy on follow-up [<a href="#rid37">37</a>]. (See <a class="local">'Malignancy'</a> below.)</p><p></p><p class="bulletIndent1">Rare cases of primary MN with dual serologic and/or tissue positivity for THSD7A and PLA2R have been reported [<a href="#rid30">30,31,38</a>]. The immunologic explanation for this finding is unknown, and the clinical features of cases with dual positivity are not different than other cases of primary MN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neural epidermal growth factor-like 1 (NELL1) </strong>– NELL1 may be the antigen responsible in approximately 16 percent of cases of PLA2R-negative primary MN or 10 percent of all biopsies showing the histologic pattern of MN [<a href="#rid39">39</a>], making it the second most common antigen after PLA2R [<a href="#rid40">40</a>]. Most patients with NELL-associated MN have no underlying disease association, but up to one-third of patients may have a concurrent malignancy [<a href="#rid41">41</a>], and cases associated with a number of drugs and toxins (alpha lipoic acid [<a href="#rid42">42</a>], bucillamine [<a href="#rid43">43,44</a>], and certain traditional indigenous medications [<a href="#rid45">45</a>]) have also been reported. Circulating anti-NELL1 antibodies have been detected patients with NELL1-associated MN. A unique histopathologic feature in NELL-associated MN is the presence of a segmental pattern of immune deposits in the glomeruli [<a href="#rid40">40,46</a>]. In addition, the predominant IgG subclass within the deposits tends to be IgG1. (See <a class="local">'Drugs'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Semaphorin 3B (Sema3B) </strong>– Sema3B has been identified as the target antigen in a unique form of primary MN that appears to involve mostly children (&lt;2 years old) and young adults [<a href="#rid47">47</a>]. Among children, kidney biopsy samples also demonstrate IgG staining along tubular basement membranes although these deposits are negative for Sema3B. Circulating antibodies against Sema3B have been detected in patients with Sema3B-associated MN. The finding of Sema3B antibodies in children with nephrotic syndrome may prove to be a valuable clue to the presence of MN rather than more common causes of childhood nephrotic syndrome like minimal change disease or focal segmental glomerulosclerosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protocadherin 7 (PCDH7)</strong> – PCDH7 was identified as a distinct target antigen in a subset (14 cases) of patients with MN whose kidney biopsies were negative for all other known antigens [<a href="#rid48">48</a>]. In this cohort, the median age was 66 years, and six patients had possible secondary associations, including Sjögren's disease/SLE, sarcoidosis, and malignancy. A unique histopathologic feature may be decreased amounts of complement factor 3, as kidney biopsy revealed only trace to 1+ staining by immunofluorescence. The presence of circulating autoantibodies to PCDH7 was demonstrated, and in one case, IgG eluted from the kidney biopsy tissue was found to be reactive with PCDH7.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exostosin 1 and 2 (EXT1 and EXT2)</strong> – EXT1 and EXT2<strong> </strong>have been identified as markers of MN associated with systemic autoimmune disease such as SLE or Sjögren's disease. In a study of patients with EXT1/EXT2-associated MN, 71 percent were positive for autoimmune autoantibodies and 35 percent had a clinical diagnosis of SLE [<a href="#rid49">49</a>]; kidney biopsy findings in these cases were also characteristic of systemic autoimmune disease. Positive EXT1/EXT2 staining is present in 30 to 40 percent of patients with pure class V LN (also known as lupus membranous nephropathy). Circulating antibodies to EXT1 and EXT2 have not yet been detected. The role of EXT1/EXT2 in disease pathogenesis has yet to be defined.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neural cell adhesion molecule 1 (NCAM1)</strong> – NCAM1<strong> </strong>was identified as a target antigen in a subset of patients of class V LN (lupus membranous nephropathy [LMN]) or MN of identified type [<a href="#rid50">50</a>]. In this report, circulating antibodies to NCAM1 were found in several cases. The patients were predominantly young females (average age 34 years) with positive testing for antinuclear antibodies (ANA). A higher-than-expected proportion of this cohort exhibited neuropsychiatric manifestations of SLE.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type III transforming growth factor beta receptor (TGFBR3)</strong> – TGFBR3<strong> </strong>was reported as a distinct biomarker in a subset of patients with class V LN [<a href="#rid51">51</a>]. In one study, 6 percent of cases of class V LN exhibited staining for TGFBR3 within the glomerular immune deposits, as opposed to none of non-LMN cases. The cohort was nearly all female, with an average age of approximately 40 years. Circulating antibodies to TGFBR3 were not detected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serine protease HTRA1 </strong>– The serine protease HTRA1 represents another target antigen in a small proportion of patients with MN [<a href="#rid52">52</a>]. In one cohort of 14 cases, the average age was 67 years, and there were only two potential secondary associations: one patient had concurrent antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis with crescentic glomerulonephritis, and another patient had been diagnosed with stage IV small cell lung cancer two years prior to kidney biopsy, at a time when there was no proteinuria. On histopathologic examination of the larger cohort, IgG4 was the predominant IgG subclass detected within the immune deposits on kidney biopsy, and levels of circulating anti-HTRA1 antibodies (also of the IgG4 subclass) suggested a correlation with proteinuria and clinical disease activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Netrin G1 (NTNG1) </strong>– NTNG1, a glycosylphosphatidylinositol-anchored membrane protein expressed in neurons and healthy podocytes, was identified as a target antigen in three patients with MN who did not have any antibodies against other antigens and did not have any other autoimmune diseases [<a href="#rid53">53</a>]. All three patients had circulating IgG4-dominant anti-NTNG1 autoantibodies, enhanced NTNG1 expression in the kidney, and glomerular IgG4 deposits. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protocadherin FAT1 (FAT1) </strong>– FAT1 may be a target antigen in patients with MN associated with hematopoietic cell transplantation. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Pathology and pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuron-derived neurotrophic factor (NDNF)</strong> – NDNF may be a target antigen in some cases of syphilis-associated MN [<a href="#rid54">54</a>]. In one series, patients with NDNF-associated MN had hump-like subepithelial immune deposits, with IgG1 as the predominant IgG subclass. NDNF colocalized with IgG within the immune deposits, and IgG eluted from the biopsy tissue reacted with NDNF by immunoblotting. The reason for the particular association with syphilis is not known.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Proprotein convertase subtilisin/kexin type 6 (PCSK6) </strong>– PCSK6 may be a target antigen in some cases of MN associated with nonsteroidal antiinflammatory drug (NSAID) use [<a href="#rid55">55</a>]. In one series of 13 patients with PCSK6-associated MN, 10 patients had a history of heavy NSAID use (<a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, or <a class="drug drug_general" data-topicid="10295" href="/z/d/drug information/10295.html" rel="external">meloxicam</a>), and 5 patients had underlying autoimmune disease. (See <a class="local">'Drugs'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutral endopeptidase (NEP) </strong>– NEP, which is expressed on podocytes, is the probable target in a rare antenatal form of MN [<a href="#rid56">56-58</a>]. The transplacental passage of anti-NEP antibodies (from mothers genetically deficient in NEP who were alloimmunized during a prior pregnancy) caused MN with subepithelial immune deposits (anti-NEP and NEP) in the fetus/neonate. Nephrotic syndrome resolved several months after birth, with disappearance of the deposits, upon clearance of the maternal antibodies. Although non–complement-fixing IgG4 was the predominant IgG subclass of anti-NEP in alloimmunized NEP-deficient mothers, the development of proteinuria in their babies correlated with the additional presence of complement-fixing IgG1 anti-NEP [<a href="#rid57">57</a>]. This finding, together with reports showing that C5b-9, the membrane attack complex, is shed into the urine of patients with recent-onset MN [<a href="#rid59">59,60</a>], provides additional evidence that the observations in Heymann nephritis are relevant to the human disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cationic bovine serum albumin</strong> – Antibodies to a cationic form of bovine serum albumin (BSA) are present in a small number of children with MN [<a href="#rid61">61</a>]. The BSA antigen, which was found within the immune deposits of biopsy specimens from these patients, is thought to be absorbed from the relatively underdeveloped pediatric intestinal tract in a partially digested or undigested form and then serve as a planted antigen within the glomerular capillary wall. Antibodies reactive with bovine, but not human, serum albumin were eluted from the kidney biopsy specimen in one case.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intracellular antigens</strong> – In addition to the target antigens noted above, antibodies directed against other antigens expressed by podocytes may contribute to the pathogenesis of MN [<a href="#rid62">62-64</a>]. In one study, serum IgG4 reactivity against aldose reductase, superoxide dismutase 2, and alpha-enolase, as well as the PLA2R and NEP, was measured in 186 patients with MN, 36 patients with focal glomerulosclerosis, and 60 patients with IgA nephropathy [<a href="#rid62">62</a>]. Elevated titers of IgG4 against the PLA2R, alpha-enolase, aldose reductase, and superoxide dismutase 2 were found in 60, 43, 34, and 28 percent of patients with MN, respectively, but not in patients with other glomerular diseases. Approximately one-half of the patients who were negative for antibodies against the PLA2R had an elevated titer for one of the other three antibodies. Although these antigens are predominantly intracellular and are probably not primarily responsible for MN, it has been proposed that podocyte injury causes the intracellular enzymes to translocate to the cell surface, where they are accessible to the circulating antibodies, causing amplification of the immune injury and possibly aggravating the course of the disease. A subsequent study has suggested that the presence and higher titers of antibodies to the intracellular antigens superoxide dismutase 2 or alpha-enolase were independently associated with poor clinical outcome [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other antigens </strong>– Using a mass spectrometric analysis of immune complexes removed from biopsy tissue, researchers have identified several other putative target antigens that may define rare novel subtypes of MN [<a href="#rid66">66,67</a>].</p><p></p><p class="bulletIndent1">Other components of the glomerular immune deposits have been identified in patients with secondary MN [<a href="#rid68">68</a>]. These include double-stranded DNA in SLE; thyroglobulin in thyroiditis; hepatitis B antigen, treponemal antigen, and <em>Helicobacter pylori</em> in the relevant infections; and carcinoembryonic antigen and prostate-specific antigen in malignancy. Their pathogenicity is unproven.</p><p></p><p class="headingAnchor" id="H2003003693"><span class="h2">Mechanisms of podocyte injury</span><span class="headingEndMark"> — </span>Several experimental models have provided insight into the mechanisms of podocyte injury in MN. These models suggest that the GBM immune deposits develop in situ with the movement across the GBM of circulating IgG antibodies directed against endogenous antigens expressed on or near the podocyte foot processes or against circulating cationic or low-molecular-weight antigens that have crossed the anionic charge barrier in the GBM.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rat model of Heymann nephritis </strong>– The pathogenic mechanisms leading to MN have been primarily elucidated from the rat model of Heymann nephritis, which closely resembles the human disease at both the clinical and histologic level [<a href="#rid69">69,70</a>]. In Heymann nephritis, circulating antibodies target the endocytic receptor megalin (gp330) on podocyte foot processes. The resultant subepithelial immune deposits activate complement, which leads to the assembly of C5b-9, the membrane attack complex, and its insertion into the podocyte plasma membrane [<a href="#rid71">71,72</a>]. Subsequent complement-mediated podocyte injury leads to two changes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Proteinuria via activation of signaling pathways in the podocyte that results in redistribution of actin and loss of slit diaphragm integrity [<a href="#rid71">71-73</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>GBM expansion by the overproduction of type IV collagen and laminin by the injured podocytes [<a href="#rid74">74-76</a>]</p><p></p><p class="bulletIndent1">Megalin is not expressed in the human glomerulus, although other antigens have been implicated in human MN, as discussed elsewhere in this topic. (See <a class="local">'Target antigens and autoantibodies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Experimental models of PLA2R- and THSD7A-associated MN </strong>– It has been difficult to directly establish the pathogenicity of human anti-PLA2R antibodies in animal models since PLA2R is not expressed by the podocytes of rodents and other experimental animals.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In vitro studies have shown that anti-PLA2R autoantibodies are able to induce complement-dependent injury of cultured human podocytes [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a transgenic mouse model in which murine PLA2R is expressed by the podocyte, passive administration of rabbit anti-PLA2R antibodies to these mice induces the formation of small subepithelial deposits, C3 deposition, and features of the nephrotic syndrome [<a href="#rid78">78</a>]. However, human anti-PLA2R antibodies do not react with the mouse PLA2R and cannot be utilized in this model.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A mouse model in which human PLA2R is expressed by mouse podocytes under the control of a podocin promoter leads to heteroimmunization with development of mouse anti-human PLA2R antibodies [<a href="#rid79">79</a>]. These mice develop full-blown nephrotic syndrome and histopathologic changes of MN by six to eight weeks of age whereas immunodeficient mice that express human PLA2R do not.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a transgenic mouse model in which a chimeric PLA2R (chPLA2R; consisting of three domains of human PLA2R and seven domains of murine PLA2R) is expressed by podocytes, the mice do not exhibit any phenotype at birth [<a href="#rid80">80</a>]. Immunization with human PLA2R induces humoral immunity to chPLA2R, nephrotic syndrome, and histopathologic changes of MN within 8 to 12 weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Passive transfer of anti-THSD7A serum from patients with MN into mice induces features of MN including proteinuria, granular immune complexes containing human IgG, and subepithelial electron-dense deposits [<a href="#rid81">81</a>]. In addition, mice injected with rabbit antibodies against human and mouse THSD7A produces a heterologous model of MN [<a href="#rid82">82</a>]. Mice actively immunized with four domains of THSD7A that are known to be targeted by anti-THDS7A antibodies in humans develop anti-THSD7A antibodies that react with endogenous mouse THSD7A, with the subsequent formation of subepithelial deposits and proteinuria [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PLA2R is expressed at the surface of the porcine podocyte and can be recognized by human anti-PLA2R. In a proof of principle study [<a href="#rid84">84</a>], human anti-PLA2R antibodies were passively transferred to a uninephrectomized minipig, which led to features typical of human MN, including histologic changes, activation of complement, and low-level proteinuria. </p><p></p><p class="headingAnchor" id="H211162432"><span class="h2">Genetic susceptibility</span><span class="headingEndMark"> — </span>Growing evidence suggests that genetic factors may be involved in the development of MN:</p><p class="bulletIndent1"><span class="glyph">●</span>A genome-wide association study that included 75 French, 146 Dutch, and 335 British individuals identified single-nucleotide polymorphisms (SNPs) at two loci that are highly associated with primary MN [<a href="#rid85">85</a>]. The two loci are within the genes for PLA2R on chromosome 2q24, and the human leukocyte antigen (HLA) complex class II alpha chain 1A (<em>HLA-DQA1</em>) on chromosome 6p21. PLA2R variants have also been found in other cohorts with primary MN, although no single variant was consistently found that could explain the association with disease [<a href="#rid86">86</a>]. (See <a class="local">'Phospholipase A2 receptor'</a> above.)</p><p></p><p class="bulletIndent1">When the French, Dutch, and British cohorts from the aforementioned genome-wide study were analyzed separately, the <em>HLA-DQA1</em> allele was associated with disease in all three populations; the <em>PLA2R1</em> allele was associated in the Dutch and British populations but not in the French, although this may have been related to the smaller sample size in the French cohort. Homozygous expression of the <em>HLA-DQA1</em> allele conferred a higher risk for disease compared with the <em>PLA2R1</em> allele (odds ratios of 20.2 versus 4.2, respectively). The homozygous expression of both alleles additively increased the risk of disease (odds ratio 78.5). These variants are also associated with MN in Chinese and Spanish patients [<a href="#rid87">87,88</a>]; in the Chinese population, homozygosity for the high-risk alleles was associated with a much higher prevalence of circulating anti-PLA2R than homozygosity for the low-risk alleles [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other analyses have used high-density SNPs to impute molecular HLA haplotypes or have directly sequenced the HLA region. In individuals of European ancestry, primary MN was significantly associated with all the alleles in the ancestral MHC8.1 haplotype, including <em>HLA-DQA1*0501</em>, <em>HLA-DQB1*0201</em>, and <em>HLA-DRB1*0301</em> [<a href="#rid89">89</a>]. Three studies regarding genetic risk for primary MN in Asian populations have identified a separate risk haplotype that includes <em>HLA-DRB1*1501</em> [<a href="#rid90">90-92</a>], indicating that genetic risk alleles within the HLA region likely differ among ethnicities. Molecular modeling in a Chinese cohort identified putative amino acids in PLA2R that might engage the binding pocket of the corresponding major histocompatibility complex (MHC) class II risk molecules [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>These collective findings were confirmed in a large genome-wide association study of 3782 cases of primary MN and 9038 controls of East Asian and European ancestry [<a href="#rid93">93</a>]. This study also identified two new loci that were highly associated with MN: one in <em>NFKB1</em> and another in <em>IRF4</em>, both encoding important molecules in immune regulation. In addition, the study described an SNP in tight linkage disequilibrium to the previously identified top locus within the first intron of <em>PLA2R1</em>; the risk allele at this position may be linked to increased expression of <em>PLA2R1 </em>exclusively in kidney tissue. A detailed analysis of the HLA locus confirmed the associations with the molecular HLA haplotypes and additionally provided evidence that the major risk in both East Asian and European populations may lie exclusively in the DR-beta chain at positions that alter discrete amino acids in the binding groove.</p><p></p><p class="headingAnchor" id="H3437687304"><span class="h2">Immune response</span><span class="headingEndMark"> — </span>Several studies provide evidence for a dysregulated immune phenotype in patients with MN. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MN have been found to have higher proportions of T helper type 17 cells and lower proportions of regulatory T cells compared with healthy individuals [<a href="#rid94">94-96</a>]. In one study, the level of regulatory T cells substantially increased in patients with a successful clinical response to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MN have been shown to have higher levels of plasma cells and regulatory B cells when compared with healthy individuals and patients with nonimmune forms of chronic kidney disease, and the percentage of circulating plasma cells correlates with levels of anti-PLA2R antibodies [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite the noninflammatory nature of the glomerular lesion in MN, circulating levels of tumor necrosis factor alpha (TNF alpha), interleukin 6 (IL-6), and IL-17 have been found to be higher among patients with MN than in healthy individuals [<a href="#rid98">98</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potential T cell epitopes on the PLA2R have been identified in patients with PLA2R-associated MN [<a href="#rid99">99</a>]. Of the 10 potential epitopes, three were in the N-terminal ricin (cysteine-rich) domain, and one overlapped with the B cell immunodominant epitope for anti-PLA2R. Many of the 10 epitopes were able to induce IL-6, TNF alpha, and IL-10 expression in vitro from peripheral blood cells collected from patients with MN, supporting prior evidence of elevated proinflammatory cytokine levels in MN.</p><p></p><p class="headingAnchor" id="H375135574"><span class="h2">Environmental factors</span><span class="headingEndMark"> — </span>Environmental factors may also play a role in the pathogenesis of MN. As an example, a study from China found an association between long-term exposure to high levels of fine particulate matter of &lt;2.5 micrometers (PM2.5) in the air and an increased risk of MN [<a href="#rid3">3</a>].</p><p>Similarly, patients with MN may be more frequently exposed to occupational toxins than the general population. In an observational study comparing the occupations and toxic occupational exposures of 100 patients with MN with those of two large cohorts of French workers without MN, patients with MN more frequently worked in the construction sector (33 versus 7 percent) and were more frequently exposed to asbestos (16 versus 5 percent), lead (9 versus 1 percent), or organic solvents (37 versus 15 percent) [<a href="#rid100">100</a>].</p><p class="headingAnchor" id="H1241214485"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>MN has traditionally been classified as either primary (or "idiopathic") or secondary, depending on the absence or presence, respectively, of diseases or exposures that were associated with and felt to be causative of the MN. The discovery of the phospholipase A2 receptor (PLA2R) and, later, thrombospondin type-1 domain-containing 7A (THSD7A), two proteins expressed by the normal podocyte, established a prototype for "primary" disease in which a humoral autoimmune response against an antigen available at the basal surface of the podocyte leads to exclusively subepithelial deposits and kidney-restricted pathology. Since then, many additional autoantigens or putative antigens have been described in forms of MN that do not fully fit this prototype of primary MN, as the proteins are not expressed by the normal podocyte (eg, neural epidermal growth factor-like 1 [NELL1]) or more often occur in association with another condition. While the field is moving toward an antigen-based classification system [<a href="#rid39">39</a>], we will continue to utilize the more traditional terms of "primary" and "secondary" in this topic, with the caveat that many if not all forms of MN may have a trigger, known or unknown, that ultimately leads to the formation of autoantibodies and/or immune complexes that target the glomerulus and result in the lesion of MN.</p><p class="headingAnchor" id="H2156711066"><span class="h2">Primary MN</span><span class="headingEndMark"> — </span>Approximately 75 percent of cases of MN in adults are considered to be primary MN. Primary MN includes forms of MN in which there is a humoral autoimmune response to a normal podocyte antigen in the absence of secondary features or etiologies of disease. Antigens implicated in primary MN include PLA2R, THSD7A, NELL1, semaphorin 3B (Sema3B), the serine protease HTRA1, protocadherin 7 (PCDH7), and others. These are discussed in more detail elsewhere in this topic. (See <a class="local">'Target antigens and autoantibodies'</a> above.)</p><p>Together, the antigens identified over the past decade account for approximately 90 percent of cases of primary MN, which means that it is likely that additional minor antigens will be added to the list in the future.</p><p class="headingAnchor" id="H348532349"><span class="h2">Secondary MN</span><span class="headingEndMark"> — </span>Secondary MN has been attributed to a variety of agents or conditions  (<a class="graphic graphic_table graphicRef80418" href="/z/d/graphic/80418.html" rel="external">table 1</a>), largely due to observations that removal of the inciting agent or treatment of the condition led to resolution of the nephrotic syndrome. These are discussed below.</p><p class="headingAnchor" id="H3034369470"><span class="h3">Systemic lupus erythematosus and other autoimmune disorders</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic lupus erythematosus </strong>– Approximately 10 to 20 percent of patients with lupus nephritis (LN) have MN, called class V LN (also called lupus membranous nephropathy [LMN]). (See  <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification"</a>.)</p><p></p><p class="bulletIndent1">Some patients with LMN present only with kidney disease and have no symptoms or serologic abnormalities suggestive of systemic lupus erythematosus (SLE), although such findings may arise several months after presentation with the nephrotic syndrome [<a href="#rid101">101,102</a>]. SLE should be suspected in any young female with apparently primary MN. In addition, there are some histologic findings on immunofluorescence (staining for IgG2, IgG3, IgA, IgM, and complement component C1q) and electron microscopy (subendothelial and subepithelial immune deposits and tubuloreticular structures in the glomerular endothelial cells) that are suggestive of underlying SLE [<a href="#rid101">101,102</a>]. PLA2R antibodies are typically negative in patients with class V LN. However, patients with PLA2R-associated primary MN may coincidently have a positive antinuclear antibody (ANA) if they also have SLE without kidney involvement. Additional features on biopsy, such as positive staining for PLA2R, lack of C1q staining, IgG4 predominance, exclusively subepithelial electron-dense deposits, and absence of tubular basement membrane staining will further help distinguish primary MN from class V LN. (See  <a class="medical medical_review" href="/z/d/html/117886.html" rel="external">"Membranous nephropathy: Clinical manifestations and diagnosis", section on 'Features distinguishing primary and secondary MN'</a>.)</p><p></p><p class="bulletIndent1">Positive immunostaining for the proteins exostosin 1 (EXT1), exostosin 2 (EXT2), neural cell adhesion molecule 1 (NCAM1), or type III transforming growth factor beta receptor (TGFBR3) may help to identify patients with class V LN. These are discussed elsewhere in this topic. (See <a class="local">'Other antigens'</a> above.)</p><p></p><p class="bulletIndent1">In case reports, LMN has been associated with a concurrent crescentic glomerulonephritis, a relationship that has also been described in primary MN. (See <a class="local">'Crescentic glomerulonephritis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgG4-related disease </strong>– IgG4-related disease is an increasingly recognized systemic syndrome of unknown etiology characterized by tumor-like swelling of involved organs, a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells, and variable degrees of fibrosis that have a characteristic "storiform" pattern. In addition, elevated serum concentrations of IgG4 are found in 60 to 70 percent of patients with IgG4-related disease. The major kidney manifestation associated with IgG4-related disease is tubulointerstitial nephritis.</p><p></p><p class="bulletIndent1">However, IgG4-related disease may also be associated with MN [<a href="#rid103">103-107</a>]. This was described in nine patients with MN who also had other manifestations of IgG4-related disease (mostly pancreatitis, tubulointerstitial nephritis, or sialadenitis) [<a href="#rid103">103</a>]. Antibodies against the PLA2R, commonly present in patients with primary MN, were absent in all patients. In addition, none of the nine patients had evidence for SLE, hepatitis virus infection, or cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other autoimmune disorders</strong> – MN has been less commonly associated with other autoimmune disorders, including Sjögren's disease [<a href="#rid108">108</a>], sarcoidosis [<a href="#rid109">109-111</a>], autoimmune thyroiditis [<a href="#rid112">112-114</a>], and ankylosing spondylitis [<a href="#rid115">115-117</a>]. (See  <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">"Kidney disease in sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/7187.html" rel="external">"Kidney disease in primary Sjögren's disease"</a>.)</p><p></p><p class="headingAnchor" id="H1409426904"><span class="h3">Drugs</span><span class="headingEndMark"> — </span>Exposure to a variety of drugs has been implicated in the development of MN, including the following [<a href="#rid42">42,45,118-129</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal antiinflammatory drugs (NSAIDs)</p><p class="bulletIndent1"><span class="glyph">●</span>Alpha lipoic acid</p><p class="bulletIndent1"><span class="glyph">●</span>Traditional indigenous medications (in India, especially those contaminated with mercury)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">Alemtuzumab</a></p><p class="bulletIndent1"><span class="glyph">●</span>Mercurial salts and elemental mercury</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-tumor necrosis factor (anti-TNF) agents (<a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, or <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">Penicillamine</a></p><p class="bulletIndent1"><span class="glyph">●</span>Gold salts</p><p class="bulletIndent1"><span class="glyph">●</span>Bucillamine</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10287" href="/z/d/drug information/10287.html" rel="external">Tiopronin</a> (2-mercaptopropionylglycine) </p><p class="bulletIndent1"><span class="glyph">●</span>High-dose <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a></p><p class="bulletIndent1"><span class="glyph">●</span>Immune checkpoint inhibitors (<a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, tislelizumab, <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a>, <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a>) [<a href="#rid130">130</a>]</p><p></p><p>The association of NSAIDs with MN was illustrated in a study of 125 patients with a biopsy diagnosis of MN [<a href="#rid118">118</a>]. Twenty-nine patients were taking an NSAID, and 13 (10 percent of the study population) fulfilled criteria for NSAID-associated MN. Many of the patients who developed MN had been treated with <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a>, but probably any NSAID can be involved [<a href="#rid118">118</a>], including cyclooxygenase 2 inhibitors [<a href="#rid120">120</a>]. Proprotein convertase subtilisin/kexin 6 (PCSK6) may be a target antigen in patients with NSAID-associated MN. (See <a class="local">'Other antigens'</a> above and  <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a>.)</p><p>The mechanisms responsible for drug-induced MN are uncertain. Human and experimental data suggest that induction of gold-specific and autoreactive T cells may lead to polyclonal B cell activation and autoantibody production in gold-induced MN [<a href="#rid131">131,132</a>]. Interestingly, it has been suggested that patients carrying the SLE-associated human leukocyte antigen (HLA) alleles <em>DRB1*0301</em> (<em>DR3</em>) and <em>DQA1*0501</em> are particularly susceptible to develop MN, as well as drug-induced lupus, after exposure to gold salts [<a href="#rid133">133</a>]. Of note, these HLA alleles have also been identified as risk alleles for primary MN in White European individuals. (See <a class="local">'Genetic susceptibility'</a> above.)</p><p>Proteinuria generally develops within the first 6 to 12 months of drug therapy but can occur as late as three to four years [<a href="#rid134">134</a>]. Discontinuation of the drug leads to resolution of the proteinuria in virtually all cases [<a href="#rid134">134,135</a>]. However, studies with <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a>, gold, and bucillamine indicate that protein excretion may continue to rise for the first 1 to 12 months (two months on average) after the cessation of therapy [<a href="#rid134">134</a>]. The mean time to resolution of the proteinuria is 9 to 12 months although two to three years are required in some cases [<a href="#rid122">122,134,135</a>]. The prolonged time to recovery may be related, in part, to the slow rate of clearance of subepithelial immune deposits and to slow remodeling of the disorganized glomerular basement membrane (GBM) [<a href="#rid75">75,136</a>].</p><p>It should be noted that MN is not the only glomerulopathy seen with these drugs. Gold and NSAIDs can lead to minimal change disease [<a href="#rid134">134</a>], whereas <a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">penicillamine</a> can induce an immune complex crescentic glomerulonephritis. Anti-TNF therapy has also been associated with the new onset of LN and pauci-immune necrotizing and crescentic glomerulonephritis [<a href="#rid123">123</a>].</p><p>Alpha lipoic acid, bucillamine, and certain traditional indigenous medications in India have been associated with NELL1-associated MN. (See <a class="local">'Other antigens'</a> above.)</p><p class="headingAnchor" id="H816614077"><span class="h3">Infections</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis B</strong> <strong>virus</strong> – MN due to hepatitis B virus (HBV) infection primarily occurs in children in endemic areas, many of whom are asymptomatic carriers with no history of active hepatitis [<a href="#rid4">4,137-139</a>]. The serum transaminases tend to be normal or only mildly elevated, and the serology is positive for HBV surface antigen, anti-core antibody, and usually e antigen. It appears that it is the e antigen and cationic anti-e antibody that are primarily deposited in the glomeruli [<a href="#rid4">4,101,138</a>].</p><p></p><p class="bulletIndent1">HBV infection and SLE represent the only forms of MN that may be associated with hypocomplementemia [<a href="#rid137">137</a>].</p><p></p><p class="bulletIndent1">Spontaneous resolution of the proteinuria is common in children with MN associated with HBV infection but not in adults, many of whom will have progressive disease [<a href="#rid138">138</a>]. (See  <a class="medical medical_review" href="/z/d/html/3119.html" rel="external">"Kidney disease associated with hepatitis B virus infection"</a>.)</p><p></p><p class="bulletIndent1">There is strong epidemiological and clinical evidence that HBV infection is responsible for secondary MN, especially in children:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The prevalence of childhood MN closely parallels the geographic distribution of HBV.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The frequency of HBV and MN in children with nephrotic syndrome in Taiwan declined from approximately 12 percent to less than 1 percent over a 20-year period following a universal vaccination program between 1984 and 2009 [<a href="#rid140">140</a>], and similar results were reported in China and South Africa.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antiviral therapy induces remission of proteinuria, especially in children and in individuals without advanced disease [<a href="#rid141">141</a>].</p><p></p><p class="bulletIndent1">Most, but not all, studies have shown a low prevalence of anti-PLA2R antibodies and/or PLA2R staining of the immune deposits in hepatitis B-associated MN [<a href="#rid5">5,14</a>]. However, one retrospective study of 39 cases of hepatitis B-associated MN found that 64 percent of cases exhibited strong PLA2R staining of immune deposits [<a href="#rid142">142</a>]. Staining for the hepatitis B surface antigen colocalized with PLA2R within the deposits. Among the six cases for which serum was available, all were positive for anti-PLA2R antibodies.</p><p></p><p class="bulletIndent1">In a series of 16 patients with MN and HBV infection, none of the patients who were positive for anti-PLA2R antibodies entered remission with antiviral therapy, whereas all of those who were negative for anti-PLA2R antibodies achieved complete remission with antiviral therapy alone [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">The association between hepatitis B infection and PLA2R-positive MN is likely to be coincidental in most cases given the high prevalence of hepatitis B infection in certain populations [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis C virus </strong>– MN may also be uncommonly associated with chronic hepatitis C virus infection [<a href="#rid143">143</a>]. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syphilis </strong>– Congenital and secondary syphilis have been associated with MN [<a href="#rid144">144-149</a>]. Treponemal antigens have been identified in the glomeruli by immunofluorescence microscopy, and eluates from glomerular deposits contain antibodies specific for <em>Treponema pallidum </em>antigen [<a href="#rid145">145,146,148</a>]. Furthermore, effective treatment of syphilis can lead to resolution of the glomerular disease [<a href="#rid145">145,147-149</a>]. (See  <a class="medical medical_review" href="/z/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1">Neuron-derived neurotrophic factor (NDNF) is a target antigen in some cases of syphilis-associated MN. (See <a class="local">'Other antigens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less common infections </strong>– MN has also been infrequently reported in association with hepatosplenic schistosomiasis, quartan malaria, and leprosy [<a href="#rid150">150-154</a>]. (See  <a class="medical medical_review" href="/z/d/html/3057.html" rel="external">"Schistosomiasis and glomerular disease"</a>.)</p><p></p><p class="headingAnchor" id="H2928521157"><span class="h3">Malignancy</span><span class="headingEndMark"> — </span>Up to 5 to 20 percent of adults with MN, particularly those over the age of 65 years, have been reported to have a malignancy, most commonly a solid tumor (principally carcinoma of the prostate, lung, breast, bladder, or gastrointestinal tract) and, less frequently, a hematologic malignancy, such as chronic lymphocytic leukemia [<a href="#rid144">144,155-161</a>].</p><p>Based upon the population examined, the risk of malignancy among those with MN can vary from 2 to 12 times higher than that observed in the general population after adjustment for age and sex [<a href="#rid159">159,160</a>]. The malignancy is presumed to be etiologically associated when there is a temporal relationship between the tumor and the MN, when removal of the tumor is followed by gradual remission of the proteinuria, and when recurrence of the malignancy is followed by return of the proteinuria. Ultimate proof of causality is the detection of tumor antigens in the GBM, but this is only rarely described [<a href="#rid162">162-165</a>]. There is a strong association between malignancy and NELL1-associated MN, in which up to one-third of patients may have a concurrent malignancy [<a href="#rid41">41</a>].</p><p>One proposed mechanism is that deposition of tumor antigens in the glomeruli promotes antibody deposition and complement activation, leading to epithelial cell and GBM injury, and consequent proteinuria [<a href="#rid162">162</a>]. The production of antibodies produced against tumor antigens that also recognize similar or identical molecules present on podocytes may be an alternative mechanism for malignancy-associated MN. (See <a class="local">'Other antigens'</a> above.)</p><p>Despite these reports, many other cases of malignancy-associated MN may represent coincident disease processes, rather than a direct causal relationship, for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>The putatively associated tumors are common in males over the age of 50 years, the same population that tends to get MN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Remission of the nephrotic syndrome with removal of the tumor does not necessarily imply a therapeutic response, since there is a relatively high rate of spontaneous remission in MN  (<a class="graphic graphic_figure graphicRef61059" href="/z/d/graphic/61059.html" rel="external">figure 2</a>).</p><p></p><p>Regardless of whether the malignancy is a causal factor or simply coincident, in many cases it has already been diagnosed or is clinically apparent at the onset of proteinuria [<a href="#rid159">159</a>]. A diagnosis of MN preceding that of malignancy is more likely in older adults [<a href="#rid155">155,159</a>]. (See  <a class="medical medical_review" href="/z/d/html/117886.html" rel="external">"Membranous nephropathy: Clinical manifestations and diagnosis", section on 'Screening for malignancy'</a>.)</p><p class="headingAnchor" id="H2816676579"><span class="h3">Hematopoietic cell transplantation</span><span class="headingEndMark"> — </span>Nephrotic syndrome occasionally arises in recipients of allogeneic stem cell or, less commonly, bone marrow transplants and is often temporally correlated with chronic graft-versus-host disease (GVHD).</p><p>MN is the most frequently reported underlying histology although minimal change disease is also seen. The occurrence of MN is often associated with a decrease in immunosuppression. FAT1 may be a target antigen in patients with MN associated with hematopoietic cell transplantation. (See  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/7197.html" rel="external">"Kidney disease following hematopoietic cell transplantation", section on 'Nephrotic syndrome'</a>.)</p><p class="headingAnchor" id="H2544247448"><span class="h3">Enzyme replacement therapy</span><span class="headingEndMark"> — </span>MN has also been documented in rare patients with hereditary enzyme deficiencies receiving enzyme replacement therapy (ERT) with recombinant human acid <a class="drug drug_general" data-topicid="9280" href="/z/d/drug information/9280.html" rel="external">alglucosidase alfa</a> (rhGAA) for lysosomal acid alpha-glucosidase deficiency (Pompe disease) and with recombinant aryl-sulfatase B (rhASB) for mucopolysaccharidosis type VI (MPS VI) [<a href="#rid166">166,167</a>]. In both cases, the recombinant enzyme was detected and colocalized with IgG in the glomerular immune deposits, and in the case of MPS VI, IgG eluted from the glomeruli was reactive with rhASB [<a href="#rid167">167</a>]. Whereas proteinuria improved in both cases with reduction or cessation of ERT, the patient with MPS VI relapsed when the lifesaving ERT was resumed and required tolerance induction therapy. Although circulating alloantibodies to porcine insulin and recombinant enzymes occur commonly, it is unclear why the "foreign" protein localizes in the glomeruli to serve as a planted antigen in such rare cases. (See  <a class="medical medical_review" href="/z/d/html/2905.html" rel="external">"Lysosomal acid alpha-glucosidase deficiency (Pompe disease, glycogen storage disease II, acid maltase deficiency)", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H3999903397"><span class="h3">MN with light chain–restricted deposits</span><span class="headingEndMark"> — </span>Cases of MN with light chain isotype–restricted deposits have been reported [<a href="#rid161">161,168-170</a>]. In the two largest series comprising 42 patients, a hematological malignancy was identified in approximately 25 percent of patients, few of whom had a detectable monoclonal protein in the serum or urine [<a href="#rid161">161,169</a>]. Systemic autoimmunity (two cases) and one case with hepatitis B and syphilis were also reported in one series; the remaining patients did not have a recognizable secondary etiology [<a href="#rid161">161</a>]. Immunofluorescence microscopy revealed kappa light chain restriction in 39 of 42 patients (93 percent) [<a href="#rid161">161,169</a>], and positive staining for PLA2R was reported in 7 of 27 patients (26 percent) in one series [<a href="#rid161">161</a>]. IgG1 subclass restriction was present in 70 percent of cases in which IgG subclass staining was available [<a href="#rid161">161,169</a>]. Patients with negative staining for PLA2R, positive staining for a single IgG subclass, and/or the presence of focal proliferation and/or crescents by light microscopy were more likely to have an underlying lymphoproliferative disorder [<a href="#rid161">161</a>]. </p><p>In rare circumstances, circulating anti-PLA2R autoantibodies may be monoclonal in nature, representing a monoclonal gammopathy of renal significance. One report details a patient with monoclonal IgG3 kappa anti-PLA2R [<a href="#rid168">168</a>]. Clinical manifestations were similar to those in primary PLA2R-associated MN although immunofluorescence of the biopsy revealed the additional presence of C1q and restriction to kappa light chain and the IgG3 subclass. The monoclonal autoantibody was also shown to cause recurrent disease in the allograft after transplantation. (See  <a class="medical medical_review" href="/z/d/html/109635.html" rel="external">"Diagnosis and treatment of monoclonal gammopathy of renal significance"</a> and <a class="local">'MN after kidney transplantation'</a> below.)</p><p class="headingAnchor" id="H4202875407"><span class="h3">Other associated conditions</span><span class="headingEndMark"> — </span>MN has been infrequently reported in association with other conditions in case reports or small series, including chronic formaldehyde exposure [<a href="#rid171">171</a>] and shortly after administration of <a class="drug drug_general" data-topicid="130318" href="/z/d/drug information/130318.html" rel="external">COVID-19 mRNA vaccines</a> [<a href="#rid172">172</a>]. </p><p class="headingAnchor" id="H3744195673"><span class="h2">MN after kidney transplantation</span><span class="headingEndMark"> — </span>MN may recur after kidney transplantation, especially if anti-PLA2R is positive at the time of transplantation, or it may occur de novo [<a href="#rid173">173</a>]. Alloimmunization against minor histocompatibility antigens or privately expressed donor epitopes may play a role in de novo MN [<a href="#rid68">68</a>]. Patients with de novo MN do not have PLA2R antigen deposits in glomerular capillaries and are nearly always anti-PLA2R antibody negative. (See  <a class="medical medical_review" href="/z/d/html/7341.html" rel="external">"Membranous nephropathy and kidney transplantation"</a>.)</p><p class="headingAnchor" id="H3354672334"><span class="h2">MN with other glomerular diseases</span><span class="headingEndMark"> — </span>MN may be seen in conjunction with other glomerular diseases. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetic kidney disease (see <a class="local">'Diabetes mellitus'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Crescentic (rapidly progressive) glomerulonephritis (see <a class="local">'Crescentic glomerulonephritis'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focal segmental glomerulosclerosis (see  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IgA nephropathy (see  <a class="medical medical_review" href="/z/d/html/3112.html" rel="external">"IgA nephropathy: Clinical features and diagnosis", section on 'Associated conditions'</a>)</p><p></p><p>It is unclear if these disorders are causally related to MN or have developed concurrently. In addition, the mechanism may vary with the second disease. With focal segmental glomerulosclerosis, for example, the sclerotic lesions may reflect a response to injury induced by the membranous disease and/or secondary intraglomerular hypertension, rather than a separate disorder [<a href="#rid174">174</a>]. Patients with these sclerotic lesions have a much higher likelihood of progressive kidney function impairment than those with uncomplicated MN and may respond less well to treatment with immunosuppressive agents [<a href="#rid175">175,176</a>]. (See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3051.html" rel="external">"Membranous nephropathy: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H3448485080"><span class="h3">Diabetes mellitus</span><span class="headingEndMark"> — </span>MN (as well as other glomerular diseases) can occur in patients with diabetes with or without diabetic kidney disease [<a href="#rid177">177,178</a>]. In a biopsy study of 220 type 2 patients with diabetes and proteinuria, nondiabetic kidney disease was present in 37 percent of patients with heavy proteinuria (average urine protein-to-creatinine ratio of 10±7.3 g/g), and of those, 42 percent had MN [<a href="#rid179">179</a>]. In most cases, the diseases are not related, but porcine insulin may be the inciting antigen in some patients. (See <a class="local">'Enzyme replacement therapy'</a> above.)</p><p class="headingAnchor" id="H2809035635"><span class="h3">Crescentic glomerulonephritis</span><span class="headingEndMark"> — </span>MN is infrequently associated with a crescentic glomerulonephritis that in some patients may be related to antineutrophil cytoplasmic antibodies (ANCA) or, less often, anti-GBM antibodies [<a href="#rid180">180-188</a>]. This relationship has mostly been described in patients with primary MN, but there are also case reports in patients with LMN [<a href="#rid189">189</a>]. (See  <a class="medical medical_review" href="/z/d/html/3108.html" rel="external">"Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Anti-GBM disease associated with membranous nephropathy'</a> and <a class="local">'Systemic lupus erythematosus and other autoimmune disorders'</a> above.)</p><p>Crescentic glomerulonephritis and the associated nephritic sediment can be superimposed upon preexisting MN or occur in conjunction with MN. In a report of 10 patients, for example, 9 had concurrent disease at presentation, and one developed crescentic glomerulonephritis five years after the original presentation of MN [<a href="#rid180">180</a>].</p><p>Why these disorders are associated with MN is not clear. One possibility is the coincident production of ANCA or anti-GBM antibodies and the antibody responsible for MN in an individual predisposed to autoimmune disorders. An alternative mechanism is that GBM injury induced by the membranous lesion may expose previously "unseen" antigens, leading to anti-GBM antibody production.</p><p>A study from a major kidney pathology laboratory identified 14 patients with both MN and ANCA-associated necrotizing and crescentic glomerulonephritis; both conditions were diagnosed simultaneously in most of these patients [<a href="#rid184">184</a>]. In a review of over 13,000 native kidney biopsies processed by the same laboratory, primary MN was present in 8.8 percent and ANCA-associated necrotizing and crescentic glomerulonephritis was present in 3.4 percent. Based upon these numbers, concurrent disease would have been expected by chance in 39 patients, well above the observed 14 cases. It was therefore concluded that concurrent disease represented a chance occurrence of two unrelated disease processes.</p><p>The findings were different in a retrospective review of 218 patients with MN; 10 (4.6 percent) had crescentic glomerulonephritis [<a href="#rid180">180</a>]. The incidence was much higher than would be expected for the random co-occurrence of the two disorders. ANCA were present in four of the nine patients who were tested. In one such case, the patient tested positive for both ANCA and anti-PLA2R [<a href="#rid190">190</a>].</p><p class="headingAnchor" id="H3486950316"><span class="h2">Membranous-like nephropathy with masked IgG-kappa</span><span class="headingEndMark"> — </span>A glomerulopathy has been described in 14 patients that is indistinguishable from MN by light microscopy and electron microscopy [<a href="#rid191">191</a>]. However, standard immunofluorescence microscopy was negative for the typical granular deposition of IgG. Only after the formalin-fixed tissue was digested with pronase were IgG deposits "unmasked." In addition, all IgG deposits consisted of IgG-kappa and not IgG-lambda. The etiology of this condition is unknown, but most of the 14 affected patients were young and had autoimmune phenomena such as inflammatory arthritis or hemolytic anemia. Another study found that the detection of serum amyloid P by immunostaining within the immune deposits may be a specific marker for this type of disease [<a href="#rid192">192</a>].</p><p class="headingAnchor" id="H1687324883"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– Membranous nephropathy (MN) is a pattern of injury found to commonly underlie the nephrotic syndrome in adults without diabetes, accounting for up to one-third of biopsy findings. MN accounts for approximately 20 to 30 percent of cases of nephrotic syndrome in White adults, and a rising incidence has been reported in China, perhaps related to environmental pollution. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis </strong>– MN is an autoimmune disorder that is characterized by thickening of the glomerular basement membrane (GBM) due to subepithelial immune complex deposition. In primary MN, circulating autoantibodies bind to endogenous antigens on the surface of glomerular podocytes, activating complement and inducing podocyte injury. In secondary MN, it is thought that circulating antigens (endogenous or exogenous), immune complexes, or even monoclonal immunoglobulins may become "planted" on the subepithelial side of the GBM and initiate immune complex formation. (See <a class="local">'Pathogenesis'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary MN </strong>– Approximately 75 percent of cases of MN in adults are primary MN. Primary MN includes forms of MN in which there is a humoral autoimmune response to a normal podocyte antigen in the absence of secondary features or etiologies of disease. Antigens implicated in primary MN include the phospholipase A2 receptor (PLA2R), thrombospondin type-1 domain-containing 7A (THSD7A), neural epidermal growth factor-like 1 (NELL1), semaphorin 3B (Sema3B), the serine protease HTRA1, protocadherin 7 (PCDH7), and others. (See <a class="local">'Primary MN'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary MN </strong>– MN has also been associated with a variety of agents or conditions  (<a class="graphic graphic_table graphicRef80418" href="/z/d/graphic/80418.html" rel="external">table 1</a>), largely due to observations that removal of the inciting agent or treatment of the condition led to resolution of the nephrotic syndrome. These include autoimmune diseases (eg, systemic lupus erythematosus [SLE]), certain drugs, infections (such as hepatitis B), malignancy, and others. (See <a class="local">'Secondary MN'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MN after kidney transplantation </strong>– MN may recur after kidney transplantation, especially if anti-PLA2R is positive at the time of transplantation, or it may occur de novo. (See  <a class="medical medical_review" href="/z/d/html/7341.html" rel="external">"Membranous nephropathy and kidney transplantation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MN with other glomerular diseases </strong>– MN may also be seen in conjunction with other glomerular diseases such as diabetic kidney disease and crescentic glomerulonephritis. (See <a class="local">'MN with other glomerular diseases'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol 2014; 36:381.</a></li><li><a class="nounderline abstract_t">Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int 2017; 91:566.</a></li><li><a class="nounderline abstract_t">Xu X, Wang G, Chen N, et al. Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China. J Am Soc Nephrol 2016; 27:3739.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Couser WG. Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37:663.</a></li><li><a class="nounderline abstract_t">Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11.</a></li><li><a class="nounderline abstract_t">Fresquet M, Jowitt TA, Gummadova J, et al. Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol 2015; 26:302.</a></li><li><a class="nounderline abstract_t">Kao L, Lam V, Waldman M, et al. Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy. J Am Soc Nephrol 2015; 26:291.</a></li><li><a class="nounderline abstract_t">Beck LH Jr. The dominant humoral epitope in phospholipase A2 receptor-1: presentation matters when serving up a slice of π. J Am Soc Nephrol 2015; 26:237.</a></li><li><a class="nounderline abstract_t">Seitz-Polski B, Dolla G, Payré C, et al. Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. J Am Soc Nephrol 2016; 27:1517.</a></li><li><a class="nounderline abstract_t">Reinhard L, Zahner G, Menzel S, et al. Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy. J Am Soc Nephrol 2020; 31:197.</a></li><li><a class="nounderline abstract_t">Seitz-Polski B, Debiec H, Rousseau A, et al. Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. J Am Soc Nephrol 2018; 29:401.</a></li><li><a class="nounderline abstract_t">Fresquet M, Lockhart-Cairns MP, Rhoden SJ, et al. Structure of PLA2R reveals presentation of the dominant membranous nephropathy epitope and an immunogenic patch. Proc Natl Acad Sci U S A 2022; 119:e2202209119.</a></li><li><a class="nounderline abstract_t">Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011; 364:689.</a></li><li><a class="nounderline abstract_t">Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22:1137.</a></li><li><a class="nounderline abstract_t">Hofstra JM, Beck LH Jr, Beck DM, et al. Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6:1286.</a></li><li><a class="nounderline abstract_t">Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1735.</a></li><li><a class="nounderline abstract_t">Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 2013; 83:940.</a></li><li><a class="nounderline abstract_t">Ruggenenti P, Debiec H, Ruggiero B, et al. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol 2015; 26:2545.</a></li><li><a class="nounderline abstract_t">Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22:1543.</a></li><li><a class="nounderline abstract_t">Burbelo PD, Joshi M, Chaturvedi A, et al. Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy. J Am Soc Nephrol 2020; 31:208.</a></li><li><a class="nounderline abstract_t">Hoxha E, Kneißler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012; 82:797.</a></li><li><a class="nounderline abstract_t">Larsen CP, Messias NC, Silva FG, et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 2013; 26:709.</a></li><li><a class="nounderline abstract_t">van de Logt AE, Hofstra JM, Wetzels JF. Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up. Kidney Int 2015; 87:1263.</a></li><li><a class="nounderline abstract_t">Francis JM, Beck LH Jr, Salant DJ. Membranous Nephropathy: A Journey From Bench to Bedside. Am J Kidney Dis 2016; 68:138.</a></li><li><a class="nounderline abstract_t">Ramachandran R, Kumar V, Nada R, Jha V. Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy. Kidney Int 2015; 88:1198.</a></li><li><a class="nounderline abstract_t">Svobodova B, Honsova E, Ronco P, et al. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant 2013; 28:1839.</a></li><li><a class="nounderline abstract_t">Segarra-Medrano A, Jatem-Escalante E, Quiles-Pérez MT, et al. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy. Nefrologia 2014; 34:353.</a></li><li><a class="nounderline abstract_t">Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371:2277.</a></li><li><a class="nounderline abstract_t">Gödel M, Grahammer F, Huber TB. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2015; 372:1073.</a></li><li><a class="nounderline abstract_t">Ren S, Wu C, Zhang Y, et al. An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN. Ren Fail 2018; 40:306.</a></li><li><a class="nounderline abstract_t">Wang J, Cui Z, Lu J, et al. Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. Clin J Am Soc Nephrol 2017; 12:1642.</a></li><li><a class="nounderline abstract_t">Zaghrini C, Seitz-Polski B, Justino J, et al. Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. Kidney Int 2019; 95:666.</a></li><li><a class="nounderline abstract_t">Iwakura T, Ohashi N, Kato A, et al. Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy. PLoS One 2015; 10:e0138841.</a></li><li><a class="nounderline abstract_t">Hoxha E, Wiech T, Stahl PR, et al. A Mechanism for Cancer-Associated Membranous Nephropathy. N Engl J Med 2016; 374:1995.</a></li><li><a class="nounderline abstract_t">Hoxha E, Beck LH Jr, Wiech T, et al. An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. J Am Soc Nephrol 2017; 28:520.</a></li><li><a class="nounderline abstract_t">Hanset N, Aydin S, Demoulin N, et al. Podocyte Antigen Staining to Identify Distinct Phenotypes and Outcomes in Membranous Nephropathy: A Retrospective Multicenter Cohort Study. Am J Kidney Dis 2020; 76:624.</a></li><li><a class="nounderline abstract_t">Sharma SG, Larsen CP. Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol 2018; 31:616.</a></li><li><a class="nounderline abstract_t">Larsen CP, Cossey LN, Beck LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol 2016; 29:421.</a></li><li><a class="nounderline abstract_t">Sethi S, Beck LH Jr, Glassock RJ, et al. Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification. Kidney Int 2023; 104:1092.</a></li><li><a class="nounderline abstract_t">Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 2020; 97:163.</a></li><li><a class="nounderline abstract_t">Caza TN, Hassen SI, Dvanajscak Z, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int 2021; 99:967.</a></li><li><a class="nounderline abstract_t">Spain RI, Andeen NK, Gibson PC, et al. Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy. Kidney Int 2021; 100:1208.</a></li><li><a class="nounderline abstract_t">Iwakura T, Ema C, Isobe S, et al. Prevalence of neural epidermal growth factor-like 1- and exostosin 1/exostosin 2-associated membranous nephropathy: a single-center retrospective study in Japan. Sci Rep 2022; 12:2967.</a></li><li><a class="nounderline abstract_t">Miyazaki R, Ueda H, Hayashi A, et al. Neural Epidermal Growth Factor-Like 1-Positive Membranous Nephropathy With Rheumatoid Arthritis. Kidney Int Rep 2023; 8:921.</a></li><li><a class="nounderline abstract_t">Kurien AA, Prema Ks J, Walker PD, Caza TN. Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy. Kidney Int 2022; 102:1424.</a></li><li><a class="nounderline abstract_t">Kudose S, Santoriello D, Debiec H, et al. The clinicopathologic spectrum of segmental membranous glomerulopathy. Kidney Int 2021; 99:247.</a></li><li><a class="nounderline abstract_t">Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int 2020; 98:1253.</a></li><li><a class="nounderline abstract_t">Sethi S, Madden B, Debiec H, et al. Protocadherin 7-Associated Membranous Nephropathy. J Am Soc Nephrol 2021; 32:1249.</a></li><li><a class="nounderline abstract_t">Sethi S, Madden BJ, Debiec H, et al. Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. J Am Soc Nephrol 2019; 30:1123.</a></li><li><a class="nounderline abstract_t">Caza TN, Hassen SI, Kuperman M, et al. Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis. Kidney Int 2021; 100:171.</a></li><li><a class="nounderline abstract_t">Caza TN, Hassen SI, Kenan DJ, et al. Transforming Growth Factor Beta Receptor 3 (TGFBR3)-Associated Membranous Nephropathy. Kidney360 2021; 2:1275.</a></li><li><a class="nounderline abstract_t">Al-Rabadi LF, Caza T, Trivin-Avillach C, et al. Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy. J Am Soc Nephrol 2021; 32:1666.</a></li><li><a class="nounderline abstract_t">Reinhard L, Machalitza M, Wiech T, et al. Netrin G1 Is a Novel Target Antigen in Primary Membranous Nephropathy. J Am Soc Nephrol 2022; 33:1823.</a></li><li><a class="nounderline abstract_t">Sethi S, Madden B, Casal Moura M, et al. Membranous Nephropathy in Syphilis is Associated with Neuron-Derived Neurotrophic Factor. J Am Soc Nephrol 2023; 34:374.</a></li><li><a class="nounderline abstract_t">Sethi S, Casal Moura M, Madden B, et al. Proprotein convertase subtilisin/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use. Kidney Int 2023; 104:343.</a></li><li><a class="nounderline abstract_t">Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346:2053.</a></li><li><a class="nounderline abstract_t">Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004; 364:1252.</a></li><li><a class="nounderline abstract_t">Nortier JL, Remiche G, Delrée P, et al. Antenatal Membranous Nephropathy and Type 2 (Axonal) Charcot-Marie-Tooth With Mutations in the Metallo-Membrane Endopeptidase Gene: A Call for Family Screening and Pharmacovigilance. Kidney Int Rep 2021; 6:1981.</a></li><li><a class="nounderline abstract_t">Schulze M, Donadio JV Jr, Pruchno CJ, et al. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 1991; 40:533.</a></li><li><a class="nounderline abstract_t">Kon SP, Coupes B, Short CD, et al. Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney Int 1995; 48:1953.</a></li><li><a class="nounderline abstract_t">Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 2011; 364:2101.</a></li><li><a class="nounderline abstract_t">Murtas C, Bruschi M, Candiano G, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 2012; 7:1394.</a></li><li><a class="nounderline abstract_t">Bruschi M, Carnevali ML, Murtas C, et al. Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. J Proteomics 2011; 74:2008.</a></li><li><a class="nounderline abstract_t">Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010; 21:507.</a></li><li><a class="nounderline abstract_t">Ghiggeri GM, Seitz-Polski B, Justino J, et al. Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy. Clin J Am Soc Nephrol 2020; 15:1762.</a></li><li><a class="nounderline abstract_t">Caza TN, Storey AJ, Hassen SI, et al. Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry. Kidney Int 2023; 103:593.</a></li><li><a class="nounderline abstract_t">Sethi S, Madden B. Mapping antigens of membranous nephropathy: almost there. Kidney Int 2023; 103:469.</a></li><li><a class="nounderline abstract_t">Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol 2005; 16:1205.</a></li><li><a class="nounderline abstract_t">Quigg RJ. Why study membranous nephropathy in rats? Kidney Int 2003; 64:2318.</a></li><li><a class="nounderline abstract_t">Farquhar MG, Saito A, Kerjaschki D, Orlando RA. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol 1995; 6:35.</a></li><li><a class="nounderline abstract_t">Cybulsky AV, Quigg RJ, Salant DJ. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol 2005; 289:F660.</a></li><li><a class="nounderline abstract_t">Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005; 16:1195.</a></li><li><a class="nounderline abstract_t">Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 2005; 16:1214.</a></li><li><a class="nounderline abstract_t">Floege J, Johnson RJ, Gordon K, et al. Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy. Kidney Int 1992; 42:573.</a></li><li><a class="nounderline abstract_t">Minto AW, Kalluri R, Togawa M, et al. Augmented expression of glomerular basement membrane specific type IV collagen isoforms (alpha3-alpha5) in experimental membranous nephropathy. Proc Assoc Am Physicians 1998; 110:207.</a></li><li><a class="nounderline abstract_t">Kim Y, Butkowski R, Burke B, et al. Differential expression of basement membrane collagen in membranous nephropathy. Am J Pathol 1991; 139:1381.</a></li><li><a class="nounderline abstract_t">Haddad G, Lorenzen JM, Ma H, et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. J Clin Invest 2021; 131.</a></li><li><a class="nounderline abstract_t">Meyer-Schwesinger C, Tomas NM, Dehde S, et al. A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients. Kidney Int 2020; 97:913.</a></li><li><a class="nounderline abstract_t">Tomas NM, Dehde S, Meyer-Schwesinger C, et al. Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice. Kidney Int 2023; 103:297.</a></li><li><a class="nounderline abstract_t">Tomas NM, Schnarre A, Dehde S, et al. Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy. Kidney Int 2023; 104:916.</a></li><li><a class="nounderline abstract_t">Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest 2016; 126:2519.</a></li><li><a class="nounderline abstract_t">Tomas NM, Meyer-Schwesinger C, von Spiegel H, et al. A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy. J Am Soc Nephrol 2017; 28:3262.</a></li><li><a class="nounderline abstract_t">Seifert L, Zahner G, Meyer-Schwesinger C, et al. The classical pathway triggers pathogenic complement activation in membranous nephropathy. Nat Commun 2023; 14:473.</a></li><li><a class="nounderline abstract_t">Reinhard L, Wiech T, Reitmeier A, et al. Pathogenicity of Human Anti-PLA 2 R1 Antibodies in Minipigs: A Pilot Study. J Am Soc Nephrol 2023; 34:369.</a></li><li><a class="nounderline abstract_t">Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364:616.</a></li><li><a class="nounderline abstract_t">Coenen MJ, Hofstra JM, Debiec H, et al. Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol 2013; 24:677.</a></li><li><a class="nounderline abstract_t">Lv J, Hou W, Zhou X, et al. Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol 2013; 24:1323.</a></li><li><a class="nounderline abstract_t">Bullich G, Ballarín J, Oliver A, et al. HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2014; 9:335.</a></li><li><a class="nounderline abstract_t">Sekula P, Li Y, Stanescu HC, et al. Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies. Nephrol Dial Transplant 2017; 32:325.</a></li><li><a class="nounderline abstract_t">Cui Z, Xie LJ, Chen FJ, et al. MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy. J Am Soc Nephrol 2017; 28:1651.</a></li><li><a class="nounderline abstract_t">Le WB, Shi JS, Zhang T, et al. HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-Related Membranous Nephropathy. J Am Soc Nephrol 2017; 28:1642.</a></li><li><a class="nounderline abstract_t">Thiri M, Honda K, Kashiwase K, et al. High-density Association Mapping and Interaction Analysis of PLA2R1 and HLA Regions with Idiopathic Membranous Nephropathy in Japanese. Sci Rep 2016; 6:38189.</a></li><li><a class="nounderline abstract_t">Xie J, Liu L, Mladkova N, et al. The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nat Commun 2020; 11:1600.</a></li><li><a class="nounderline abstract_t">Rosenzwajg M, Languille E, Debiec H, et al. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney Int 2017; 92:227.</a></li><li><a class="nounderline abstract_t">Motavalli R, Etemadi J, Soltani-Zangbar MS, et al. Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy. Cytokine 2021; 141:155452.</a></li><li><a class="nounderline abstract_t">Ma DH, Yang XD, Hua QJ, et al. Changes and significance of Treg and Th17 in adult patients with primary membranous nephropathy. Clin Nephrol 2021; 96:155.</a></li><li><a class="nounderline abstract_t">Cantarelli C, Jarque M, Angeletti A, et al. A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients. Kidney Int Rep 2020; 5:1764.</a></li><li><a class="nounderline abstract_t">Cremoni M, Brglez V, Perez S, et al. Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses. Front Immunol 2020; 11:574997.</a></li><li><a class="nounderline abstract_t">Zhang XD, Lin CX, Cui Z, et al. Mapping the T cell epitopes of the M-type transmembrane phospholipase A2 receptor in primary membranous nephropathy. Kidney Int 2023; 103:580.</a></li><li><a class="nounderline abstract_t">Cremoni M, Agbekodo S, Teisseyre M, et al. Toxic Occupational Exposures and Membranous Nephropathy. Clin J Am Soc Nephrol 2022; 17:1609.</a></li><li><a class="nounderline abstract_t">Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983; 24:377.</a></li><li><a class="nounderline abstract_t">Comparison of idiopathic and systemic lupus erythematosus-associated membranous glomerulonephropathy in children. The Southwest Pediatric Nephrology Study Group. Am J Kidney Dis 1986; 7:115.</a></li><li><a class="nounderline abstract_t">Alexander MP, Larsen CP, Gibson IW, et al. Membranous glomerulonephritis is a manifestation of IgG4-related disease. Kidney Int 2013; 83:455.</a></li><li><a class="nounderline abstract_t">Saeki T, Imai N, Ito T, et al. Membranous nephropathy associated with IgG4-related systemic disease and without autoimmune pancreatitis. Clin Nephrol 2009; 71:173.</a></li><li><a class="nounderline abstract_t">Jindal N, Yadav D, Passero C, et al. Membranous nephropathy: a rare renal manifestation of IgG4-related systemic disease. Clin Nephrol 2012; 77:321.</a></li><li><a class="nounderline abstract_t">Cravedi P, Abbate M, Gagliardini E, et al. Membranous nephropathy associated with IgG4-related disease. Am J Kidney Dis 2011; 58:272.</a></li><li><a class="nounderline abstract_t">Fervenza FC, Downer G, Beck LH Jr, Sethi S. IgG4-related tubulointerstitial nephritis with membranous nephropathy. Am J Kidney Dis 2011; 58:320.</a></li><li><a class="nounderline abstract_t">Yang HX, Wang J, Wen YB, et al. Renal involvement in primary Sjögren's syndrome: A retrospective study of 103 biopsy-proven cases from a single center in China. Int J Rheum Dis 2018; 21:223.</a></li><li><a class="nounderline abstract_t">Stehlé T, Joly D, Vanhille P, et al. Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study. Orphanet J Rare Dis 2013; 8:65.</a></li><li><a class="nounderline abstract_t">Aydi Z, Ben Dhaou B, Baili L, et al. [Systemic sarcoidosis and membranous glomerulonephritis]. Rev Pneumol Clin 2014; 70:375.</a></li><li><a class="nounderline abstract_t">Zubidat D, Madden B, Kudose S, et al. Heterogeneity of Target Antigens in Sarcoidosis-Associated Membranous Nephropathy. Kidney Int Rep 2023; 8:1213.</a></li><li><a class="nounderline abstract_t">Shima Y, Nakanishi K, Togawa H, et al. Membranous nephropathy associated with thyroid-peroxidase antigen. Pediatr Nephrol 2009; 24:605.</a></li><li><a class="nounderline abstract_t">Sasaki K, Yasuda K, Nakanishi K, et al. Membranous nephropathy secondary to Graves' disease with deposits of thyroid peroxidase in an adult. CEN Case Rep 2014; 3:90.</a></li><li><a class="nounderline abstract_t">Thajudeen B, John SG, Ossai NO, et al. Membranous nephropathy with crescents in a patient with Hashimoto's thyroiditis: a case report. Medicine (Baltimore) 2014; 93:e63.</a></li><li><a class="nounderline abstract_t">Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 1998; 17:524.</a></li><li><a class="nounderline abstract_t">Gupta R, Sharma A, Arora R, et al. Membranous glomerulonephritis in a patient with ankylosing spondylitis: a rare association. Clin Exp Nephrol 2009; 13:667.</a></li><li><a class="nounderline abstract_t">Chen R, Li F, Xie Q, et al. Membranous nephropathy in a patient with ankylosing spondylitis: A case report. Medicine (Baltimore) 2017; 96:e8201.</a></li><li><a class="nounderline abstract_t">Radford MG Jr, Holley KE, Grande JP, et al. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996; 276:466.</a></li><li><a class="nounderline abstract_t">Campistol JM, Galofre J, Botey A, et al. Reversible membranous nephritis associated with diclofenac. Nephrol Dial Transplant 1989; 4:393.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Falkowitz DC, Isom R, et al. Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. Clin Nephrol 2003; 59:137.</a></li><li><a class="nounderline abstract_t">Nagahama K, Matsushita H, Hara M, et al. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis 2002; 39:706.</a></li><li><a class="nounderline abstract_t">Hoshino J, Ubara Y, Hara S, et al. Outcome and treatment of bucillamine-induced nephropathy. Nephron Clin Pract 2006; 104:c15.</a></li><li><a class="nounderline abstract_t">Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20:1400.</a></li><li><a class="nounderline abstract_t">Chin G, Luxton G, Harvey JM. Infliximab and nephrotic syndrome. Nephrol Dial Transplant 2005; 20:2824.</a></li><li><a class="nounderline abstract_t">den Broeder AA, Assmann KJ, van Riel PL, Wetzels JF. Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth J Med 2003; 61:137.</a></li><li><a class="nounderline abstract_t">Li SJ, Zhang SH, Chen HP, et al. Mercury-induced membranous nephropathy: clinical and pathological features. Clin J Am Soc Nephrol 2010; 5:439.</a></li><li><a class="nounderline abstract_t">Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 2011; 77:573.</a></li><li><a class="nounderline abstract_t">Plaza JJ, Herrero G, Barat A, et al. Membranous glomerulonephritis as a complication of oral gold therapy. Ann Intern Med 1982; 97:563.</a></li><li><a class="nounderline abstract_t">Wilson AP, Prouse PJ, Gumpel JM. Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria. Ann Rheum Dis 1984; 43:511.</a></li><li><a class="nounderline abstract_t">Benyahia R, Lazareth H, Flahault A, et al. Membranous Nephropathy After Exposure to Immune Checkpoint Inhibitors. Kidney Int Rep 2023; 8:1892.</a></li><li><a class="nounderline abstract_t">Romagnoli P, Spinas GA, Sinigaglia F. Gold-specific T cells in rheumatoid arthritis patients treated with gold. J Clin Invest 1992; 89:254.</a></li><li><a class="nounderline abstract_t">Tournade H, Guery JC, Pasquier R, et al. Experimental gold-induced autoimmunity. Nephrol Dial Transplant 1991; 6:621.</a></li><li><a class="nounderline abstract_t">Gunnarsson I, Ringertz B, Bratt J, Sundelin B. HLA-DRB1*0301 and DQA1*0501 in RA. Ann Rheum Dis 2001; 60:727.</a></li><li><a class="nounderline abstract_t">Katz WA, Blodgett RC Jr, Pietrusko RG. Proteinuria in gold-treated rheumatoid arthritis. Ann Intern Med 1984; 101:176.</a></li><li><a class="nounderline abstract_t">Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296:1083.</a></li><li><a class="nounderline abstract_t">Fries JW, Mendrick DL, Rennke HG. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988; 34:333.</a></li><li><a class="nounderline abstract_t">Yoshikawa N, Ito H, Yamada Y, et al. Membranous glomerulonephritis associated with hepatitis B antigen in children: a comparison with idiopathic membranous glomerulonephritis. Clin Nephrol 1985; 23:28.</a></li><li><a class="nounderline abstract_t">Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324:1457.</a></li><li><a class="nounderline abstract_t">Seggie J, Davies PG, Ninin D, Henry J. Patterns of glomerulonephritis in Zimbabwe: survey of disease characterised by nephrotic proteinuria. Q J Med 1984; 53:109.</a></li><li><a class="nounderline abstract_t">Liao MT, Chang MH, Lin FG, et al. Universal hepatitis B vaccination reduces childhood hepatitis B virus-associated membranous nephropathy. Pediatrics 2011; 128:e600.</a></li><li><a class="nounderline abstract_t">Yang Y, Ma YP, Chen DP, et al. A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy. PLoS One 2016; 11:e0160437.</a></li><li><a class="nounderline abstract_t">Xie Q, Li Y, Xue J, et al. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol 2015; 41:345.</a></li><li><a class="nounderline abstract_t">Stehman-Breen C, Alpers CE, Couser WG, et al. Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol 1995; 44:141.</a></li><li><a class="nounderline abstract_t">Cahen R, Francois B, Trolliet P, et al. Aetiology of membranous glomerulonephritis: a prospective study of 82 adult patients. Nephrol Dial Transplant 1989; 4:172.</a></li><li><a class="nounderline abstract_t">Gamble CN, Reardan JB. Immunopathogenesis of syphilitic glomerulonephritis. Elution of antitreponemal antibody from glomerular immune-complex deposits. N Engl J Med 1975; 292:449.</a></li><li><a class="nounderline abstract_t">O'Regan S, Fong JS, de Chadarévian JP, et al. Treponemal antigens in congenital and acquired syphilitic nephritis: demonstration by immunofluorescence studies. Ann Intern Med 1976; 85:325.</a></li><li><a class="nounderline abstract_t">Hunte W, al-Ghraoui F, Cohen RJ. Secondary syphilis and the nephrotic syndrome. J Am Soc Nephrol 1993; 3:1351.</a></li><li><a class="nounderline abstract_t">Losito A, Bucciarelli E, Massi-Benedetti F, Lato M. Membranous glomerulonephritis in congenital syphilis. Clin Nephrol 1979; 12:32.</a></li><li><a class="nounderline abstract_t">Yuceoglu AM, Sagel I, Tresser G, et al. The glomerulopathy of congenital syphilis. A curable immune-deposit disease. JAMA 1974; 229:1085.</a></li><li><a class="nounderline abstract_t">Neves PD, Bezerra KS, Silveira MA, et al. Schistosoma mansoni and membranous nephropathy. Kidney Int 2016; 89:959.</a></li><li><a class="nounderline abstract_t">Liao ZN, Tao LJ, Yin HL, et al. Schistosoma japonicum infection associated with membranous nephropathy: a case report. BMC Infect Dis 2022; 22:125.</a></li><li><a class="nounderline abstract_t">Mohammad Ibrahim WH, Aly MG, Abdo MK, Ismail W. Primary Membranous Glomerulonephritis-associated with Schistosomal Nephropathy. Indian J Nephrol 2019; 29:140.</a></li><li><a class="nounderline abstract_t">van Velthuysen ML, Florquin S. Glomerulopathy associated with parasitic infections. Clin Microbiol Rev 2000; 13:55.</a></li><li><a class="nounderline abstract_t">Seedat YK. Glomerular disease in the tropics. Semin Nephrol 2003; 23:12.</a></li><li><a class="nounderline abstract_t">Burstein DM, Korbet SM, Schwartz MM. Membranous glomerulonephritis and malignancy. Am J Kidney Dis 1993; 22:5.</a></li><li><a class="nounderline abstract_t">Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int 1999; 56:355.</a></li><li><a class="nounderline abstract_t">Da'as N, Polliack A, Cohen Y, et al. Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur J Haematol 2001; 67:158.</a></li><li><a class="nounderline abstract_t">Rihova Z, Honsova E, Merta M, et al. Secondary membranous nephropathy--one center experience. Ren Fail 2005; 27:397.</a></li><li><a class="nounderline abstract_t">Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 2006; 70:1510.</a></li><li><a class="nounderline abstract_t">Bjørneklett R, Vikse BE, Svarstad E, et al. Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 2007; 50:396.</a></li><li><a class="nounderline abstract_t">Best Rocha A, Larsen CP. Membranous Glomerulopathy With Light Chain-Restricted Deposits: A Clinicopathological Analysis of 28 Cases. Kidney Int Rep 2017; 2:1141.</a></li><li><a class="nounderline abstract_t">Couser WG, Wagonfeld JB, Spargo BH, Lewis EJ. Glomerular deposition of tumor antigen in membranous nephropathy associated with colonic carcinoma. Am J Med 1974; 57:962.</a></li><li><a class="nounderline abstract_t">Wakashin M, Wakashin Y, Iesato K, et al. Association of gastric cancer and nephrotic syndrome. An immunologic study in three patients. Gastroenterology 1980; 78:749.</a></li><li><a class="nounderline abstract_t">Kerpen HO, Bhat JG, Feiner HD, Baldwin DS. Membranes nephropathy associated with renal cell carcinoma. Evidence against a role of renal tubular or tumor antibodies in pathogenesis. Am J Med 1978; 64:863.</a></li><li><a class="nounderline abstract_t">Togawa A, Yamamoto T, Suzuki H, et al. Membranous glomerulonephritis associated with renal cell carcinoma: failure to detect a nephritogenic tumor antigen. Nephron 2002; 90:219.</a></li><li><a class="nounderline abstract_t">Hunley TE, Corzo D, Dudek M, et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics 2004; 114:e532.</a></li><li><a class="nounderline abstract_t">Debiec H, Valayannopoulos V, Boyer O, et al. Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy. J Am Soc Nephrol 2014; 25:675.</a></li><li><a class="nounderline abstract_t">Debiec H, Hanoy M, Francois A, et al. Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor. J Am Soc Nephrol 2012; 23:1949.</a></li><li><a class="nounderline abstract_t">Guiard E, Karras A, Plaisier E, et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 2011; 6:1609.</a></li><li><a class="nounderline abstract_t">Komatsuda A, Masai R, Ohtani H, et al. Monoclonal immunoglobulin deposition disease associated with membranous features. Nephrol Dial Transplant 2008; 23:3888.</a></li><li><a class="nounderline abstract_t">Breysse P, Couser WG, Alpers CE, et al. Membranous nephropathy and formaldehyde exposure. Ann Intern Med 1994; 120:396.</a></li><li><a class="nounderline abstract_t">Gueguen L, Loheac C, Saidani N, Khatchatourian L. Membranous nephropathy following anti-COVID-19 mRNA vaccination. Kidney Int 2021; 100:1140.</a></li><li><a class="nounderline abstract_t">Kattah A, Ayalon R, Beck LH Jr, et al. Anti-phospholipase A₂ receptor antibodies in recurrent membranous nephropathy. Am J Transplant 2015; 15:1349.</a></li><li><a class="nounderline abstract_t">Morita M, Mii A, Shimizu A, et al. Glomerular endothelial cell injury and focal segmental glomerulosclerosis lesion in idiopathic membranous nephropathy. PLoS One 2015; 10:e0116700.</a></li><li><a class="nounderline abstract_t">Wakai S, Magil AB. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int 1992; 41:428.</a></li><li><a class="nounderline abstract_t">Dumoulin A, Hill GS, Montseny JJ, Meyrier A. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Am J Kidney Dis 2003; 41:38.</a></li><li><a class="nounderline abstract_t">Bertani T, Appel GB, D'Agati V, et al. Focal segmental membranous glomerulonephropathy associated with other glomerular diseases. Am J Kidney Dis 1983; 2:439.</a></li><li><a class="nounderline abstract_t">Furuta T, Seino J, Saito T, et al. Insulin deposits in membranous nephropathy associated with diabetes mellitus. Clin Nephrol 1992; 37:65.</a></li><li><a class="nounderline abstract_t">Lee YH, Kim KP, Kim YG, et al. Clinicopathological features of diabetic and nondiabetic renal diseases in type 2 diabetic patients with nephrotic-range proteinuria. Medicine (Baltimore) 2017; 96:e8047.</a></li><li><a class="nounderline abstract_t">Tse WY, Howie AJ, Adu D, et al. Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases. Nephrol Dial Transplant 1997; 12:1017.</a></li><li><a class="nounderline abstract_t">James SH, Lien YH, Ruffenach SJ, Wilcox GE. Acute renal failure in membranous glomerulonephropathy: a result of superimposed crescentic glomerulonephritis. J Am Soc Nephrol 1995; 6:1541.</a></li><li><a class="nounderline abstract_t">Sano T, Kamata K, Shigematsu H, Kobayashi Y. A case of anti-glomerular basement membrane glomerulonephritis superimposed on membranous nephropathy. Nephrol Dial Transplant 2000; 15:1238.</a></li><li><a class="nounderline abstract_t">Dwyer KM, Agar JW, Hill PA, Murphy BF. Membranous nephropathy and anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: a report of 2 cases. Clin Nephrol 2001; 56:394.</a></li><li><a class="nounderline abstract_t">Nasr SH, Said SM, Valeri AM, et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol 2009; 4:299.</a></li><li><a class="nounderline abstract_t">Nasr SH, Ilamathi ME, Markowitz GS, D'Agati VD. A dual pattern of immunofluorescence positivity. Am J Kidney Dis 2003; 42:419.</a></li><li><a class="nounderline abstract_t">Rodriguez EF, Nasr SH, Larsen CP, et al. Membranous nephropathy with crescents: a series of 19 cases. Am J Kidney Dis 2014; 64:66.</a></li><li><a class="nounderline abstract_t">Alawieh R, Brodsky SV, Satoskar AA, et al. Membranous Nephropathy With Crescents. Kidney Int Rep 2020; 5:537.</a></li><li><a class="nounderline abstract_t">Nikolopoulou A, Huang-Doran I, McAdoo SP, et al. Membranous Glomerulonephritis With Crescents. Kidney Int Rep 2019; 4:1577.</a></li><li><a class="nounderline abstract_t">Marshall S, Dressler R, D'Agati V. Membranous lupus nephritis with antineutrophil cytoplasmic antibody-associated segmental necrotizing and crescentic glomerulonephritis. Am J Kidney Dis 1997; 29:119.</a></li><li><a class="nounderline abstract_t">Surindran S, Ayalon R, Hasan N, et al. Coexistence of ANCA-associated glomerulonephritis and anti-phospholipase A(2) receptor antibody-positive membranous nephropathy. Clin Kidney J 2012; 5:162.</a></li><li><a class="nounderline abstract_t">Larsen CP, Ambuzs JM, Bonsib SM, et al. Membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 2014; 86:154.</a></li><li><a class="nounderline abstract_t">Larsen CP, Sharma SG, Caza TN, et al. Serum amyloid P deposition is a sensitive and specific feature of membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 2020; 97:602.</a></li></ol></div><div id="topicVersionRevision">Topic 3050 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24715030" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Immunopathogenesis of membranous nephropathy: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28065518" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Membranous nephropathy: integrating basic science into improved clinical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27365535" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1968522" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19571279" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25288605" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25205735" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25288604" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The dominant humoral epitope in phospholipase A2 receptor-1: presentation matters when serving up a slice ofπ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26567246" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31843985" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114041" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35858348" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Structure of PLA2R reveals presentation of the dominant membranous nephropathy epitope and an immunogenic patch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21323563" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21566055" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anti-phospholipase A2 receptor antibody in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21474589" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Anti-phospholipase A₂receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22956816" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23364522" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25804280" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21784898" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31843984" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22673885" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23196797" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26024039" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Serum anti-PLA2R antibodies can be initially absent in idiopathic membranous nephropathy: seroconversion after prolonged follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27085376" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Membranous Nephropathy: A Journey From Bench to Bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26579688" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Serial monitoring of anti-PLA2R in initial PLA2R-negative patients with primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23223223" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24798555" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25394321" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25760365" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29623759" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : An update on clinical significance of use of THSD7A in diagnosing idiopathic membranous nephropathy: a systematic review and meta-analysis of THSD7A in IMN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28801527" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30784662" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26393352" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27192690" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A Mechanism for Cancer-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27436855" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32668319" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Podocyte Antigen Staining to Identify Distinct Phenotypes and Outcomes in Membranous Nephropathy: A Retrospective Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29243738" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26847174" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37795587" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31901340" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32828756" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : NELL1 is a target antigen in malignancy-associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34662650" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)-associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35194125" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevalence of neural epidermal growth factor-like 1- and exostosin 1/exostosin 2-associated membranous nephropathy: a single-center retrospective study in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37069980" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Neural Epidermal Growth Factor-Like 1-Positive Membranous Nephropathy With Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36096266" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Traditional indigenous medicines are an etiologic consideration for NELL1-positive membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32599086" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The clinicopathologic spectrum of segmental membranous glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32534052" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33833079" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Protocadherin 7-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31061139" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33045259" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35369660" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transforming Growth Factor Beta Receptor 3 (TGFBR3)-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33952630" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Serine Protease HTRA1 as a Novel Target Antigen in Primary Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35985817" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Netrin G1 Is a Novel Target Antigen in Primary Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36857498" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Membranous Nephropathy in Syphilis is Associated with Neuron-Derived Neurotrophic Factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37119877" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Proprotein convertase subtilisin/kexin type 6 (PCSK6) is a likely antigenic target in membranous nephropathy and nonsteroidal anti-inflammatory drug use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12087141" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15464186" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34307994" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Antenatal Membranous Nephropathy and Type 2 (Axonal) Charcot-Marie-Tooth With Mutations in the Metallo-Membrane Endopeptidase Gene: A Call for Family Screening and Pharmacovigilance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1787650" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Elevated urinary excretion of the C5b-9 complex in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8587257" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21631322" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Early-childhood membranous nephropathy due to cationic bovine serum albumin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22773590" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21640210" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20150532" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Autoimmunity in membranous nephropathy targets aldose reductase and SOD2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33257410" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36638888" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36822753" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Mapping antigens of membranous nephropathy: almost there.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800120" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633157" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Why study membranous nephropathy in rats?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579068" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The Heymann nephritis antigenic complex: megalin (gp330) and RAP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16159900" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Experimental membranous nephropathy redux.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800119" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cellular response to injury in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800113" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Contrasting roles of complement activation and its regulation in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1383596" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Altered glomerular extracellular matrix synthesis in experimental membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9625527" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Augmented expression of glomerular basement membrane specific type IV collagen isoforms (alpha3-alpha5) in experimental membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1750509" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Differential expression of basement membrane collagen in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33351779" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32033781" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36191868" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37598854" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27214550" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814510" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36709213" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The classical pathway triggers pathogenic complement activation in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36735391" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pathogenicity of Human Anti-PLA 2 R1 Antibodies in Minipigs: A Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21323541" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23431073" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813219" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24262501" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27333618" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27852637" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28028136" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-Related Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27934873" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : High-density Association Mapping and Interaction Analysis of PLA2R1 and HLA Regions with Idiopathic Membranous Nephropathy in Japanese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32231244" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28318628" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33571932" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33993908" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Changes and significance of Treg and Th17 in adult patients with primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33102969" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33324398" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36549363" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mapping the T cell epitopes of the M-type transmembrane phospholipase A2 receptor in primary membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36283759" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Toxic Occupational Exposures and Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6358633" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pathologic differentiation between lupus and nonlupus membranous glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3484901" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Comparison of idiopathic and systemic lupus erythematosus-associated membranous glomerulonephropathy in children. The Southwest Pediatric Nephrology Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23254897" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Membranous glomerulonephritis is a manifestation of IgG4-related disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19203510" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Membranous nephropathy associated with IgG4-related systemic disease and without autoimmune pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22445476" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Membranous nephropathy: a rare renal manifestation of IgG4-related systemic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658826" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Membranous nephropathy associated with IgG4-related disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21705127" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : IgG4-related tubulointerstitial nephritis with membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28941123" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Renal involvement in primary Sjögren's syndrome: A retrospective study of 103 biopsy-proven cases from a single center in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23631446" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Clinicopathological study of glomerular diseases associated with sarcoidosis: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25459352" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : [Systemic sarcoidosis and membranous glomerulonephritis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37284677" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Heterogeneity of Target Antigens in Sarcoidosis-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18762990" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Membranous nephropathy associated with thyroid-peroxidase antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28509253" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Membranous nephropathy secondary to Graves' disease with deposits of thyroid peroxidase in an adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25121358" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Membranous nephropathy with crescents in a patient with Hashimoto's thyroiditis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9890685" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19652903" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Membranous glomerulonephritis in a patient with ankylosing spondylitis: a rare association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29068987" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Membranous nephropathy in a patient with ankylosing spondylitis: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8691554" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2505191" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Reversible membranous nephritis associated with diclofenac.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12608557" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920335" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Bucillamine induces membranous glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685139" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Outcome and treatment of bucillamine-induced nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15840673" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204273" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Infliximab and nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12852723" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089494" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Mercury-induced membranous nephropathy: clinical and pathological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21795656" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6812474" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Membranous glomerulonephritis as a complication of oral gold therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6430252" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37705909" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Membranous Nephropathy After Exposure to Immune Checkpoint Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1729275" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Gold-specific T cells in rheumatoid arthritis patients treated with gold.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1745385" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Experimental gold-induced autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11436868" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : HLA-DRB1*0301 and DQA1*0501 in RA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6430141" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Proteinuria in gold-treated rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3132218" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Natural course of penicillamine nephropathy: a long term study of 33 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2971836" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Determinants of immune complex-mediated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3978879" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Membranous glomerulonephritis associated with hepatitis B antigen in children: a comparison with idiopathic membranous glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2023605" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Membranous nephropathy related to hepatitis B virus in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6369374" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Patterns of glomerulonephritis in Zimbabwe: survey of disease characterised by nephrotic proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21859911" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Universal hepatitis B vaccination reduces childhood hepatitis B virus-associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27598699" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : A Meta-Analysis of Antiviral Therapy for Hepatitis B Virus-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26087695" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8556829" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Hepatitis C virus associated membranous glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2498774" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Aetiology of membranous glomerulonephritis: a prospective study of 82 adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1089888" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Immunopathogenesis of syphilitic glomerulonephritis. Elution of antitreponemal antibody from glomerular immune-complex deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/786093" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Treponemal antigens in congenital and acquired syphilitic nephritis: demonstration by immunofluorescence studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439646" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Secondary syphilis and the nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/383337" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Membranous glomerulonephritis in congenital syphilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4276729" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : The glomerulopathy of congenital syphilis. A curable immune-deposit disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26994579" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Schistosoma mansoni and membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35123391" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Schistosoma japonicum infection associated with membranous nephropathy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30983758" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Primary Membranous Glomerulonephritis-associated with Schistosomal Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10627491" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Glomerulopathy associated with parasitic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12563597" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Glomerular disease in the tropics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8322793" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Membranous glomerulonephritis and malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411717" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Paraneoplastic glomerulopathies: new insights into an old entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737248" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16060126" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Secondary membranous nephropathy--one center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16941021" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17720518" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Long-term risk of cancer in membranous nephropathy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29270522" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Membranous Glomerulopathy With Light Chain-Restricted Deposits: A Clinicopathological Analysis of 28 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4139896" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Glomerular deposition of tumor antigen in membranous nephropathy associated with colonic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6986318" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Association of gastric cancer and nephrotic syndrome. An immunologic study in three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/645750" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Membranes nephropathy associated with renal cell carcinoma. Evidence against a role of renal tubular or tumor antibodies in pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11818710" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Membranous glomerulonephritis associated with renal cell carcinoma: failure to detect a nephritogenic tumor antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466083" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24262793" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23123401" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Recurrent membranous nephropathy in an allograft caused by IgG3κtargeting the PLA2 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21700823" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18596130" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Monoclonal immunoglobulin deposition disease associated with membranous features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8304657" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Membranous nephropathy and formaldehyde exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34419553" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Membranous nephropathy following anti-COVID-19 mRNA vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25766759" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Anti-phospholipase A₂receptor antibodies in recurrent membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25875837" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Glomerular endothelial cell injury and focal segmental glomerulosclerosis lesion in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552716" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Focal glomerulosclerosis in idiopathic membranous glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12500220" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6823961" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Focal segmental membranous glomerulonephropathy associated with other glomerular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1551252" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Insulin deposits in membranous nephropathy associated with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28885376" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Clinicopathological features of diabetic and nondiabetic renal diseases in type 2 diabetic patients with nephrotic-range proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9175062" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8749678" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Acute renal failure in membranous glomerulonephropathy: a result of superimposed crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10910453" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : A case of anti-glomerular basement membrane glomerulonephritis superimposed on membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11758012" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Membranous nephropathy and anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: a report of 2 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158367" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12900828" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : A dual pattern of immunofluorescence positivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24709471" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Membranous nephropathy with crescents: a series of 19 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32274459" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Membranous Nephropathy With Crescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31890999" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Membranous Glomerulonephritis With Crescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9002540" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Membranous lupus nephritis with antineutrophil cytoplasmic antibody-associated segmental necrotizing and crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22833809" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Coexistence of ANCA-associated glomerulonephritis and anti-phospholipase A(2) receptor antibody-positive membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24429395" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Membranous-like glomerulopathy with masked IgG kappa deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32001064" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Serum amyloid P deposition is a sensitive and specific feature of membranous-like glomerulopathy with masked IgG kappa deposits.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
